Literature DB >> 10714607

Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.

M L van Slooten1, G Storm, A Zoephel, Z Küpcü, O Boerman, D J Crommelin, E Wagner, R Kircheis.   

Abstract

PURPOSE: Liposomal systems may be useful as a cytokine supplement in tumor cell vaccines by providing a cytokine reservoir at the antigen presentation site. Here, we examined the effect of liposome incorporation of mIFNgamma on its potency as adjuvant in an established tumor cell vaccination protocol in the murine B16 melanoma model. Adjuvanticity of the mIFNgamma-liposomes was compared to that achieved by mIFNgamma-gene transfection of the B16 tumor cells. Furthermore, we studied whether liposomal incorporation of mIFNgamma indeed increases the residence time of the cytokine at the vaccination site.
METHODS: C57B1/6 mice were immunized with i) irradiated IFNgamma-gene transfected B16 melanoma cells or ii) irradiated wild type B16 cells supplemented with (liposomal) mIFNgamma, followed by a challenge with viable B16 cells. The residence time of the (liposomal) cytokine at the subcutaneous (s.c.) vaccination site was monitored using radiolabeled mIFNgamma and liposomes.
RESULTS: Immunization with irradiated tumor cells admixed with liposomal mIFNgamma generated comparable protection against B16 challenge as immunization with mIFNgamma-gene modified tumor cells. Irradiated tumor cells admixed with soluble mIFNgamma did not generate any protective responses. Radiolabeling studies indicated that free mIFNgamma rapidly cleared from the s.c. injection site. Association of [125I]-mIFNgamma with liposomes increased the local residence time substantially: liposomal association of mIFNgamma resulted in a prolonged local residence time of the cytokine as reflected by a 4-fold increase of the area under the curve. The amount of released cytokine in the optimal dose range corresponds to the amount released by the gene-transfected cells. Moderate but significant CTL-activity against B16 cells was found for mice immunized with irradiated cells supplemented with mIFNgamma-liposomes compared to untreated control animals.
CONCLUSIONS: Prolonged presence of mIFNgamma at the site of antigen presentation is crucial for the generation of systemic immune responses in the B16 melanoma model. These studies show that liposomal encapsulation of cytokines is an attractive strategy for paracrine cytokine delivery in tumor vaccine development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10714607     DOI: 10.1023/a:1007514424253

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose.

Authors:  C Oussoren; J Zuidema; D J Crommelin; G Storm
Journal:  Biochim Biophys Acta       Date:  1997-09-04

Review 2.  Melanoma and vitiligo: immunology's Grecian urn.

Authors:  D Berd; M J Mastrangelo; E Lattime; T Sato; H C Maguire
Journal:  Cancer Immunol Immunother       Date:  1996-06       Impact factor: 6.968

3.  Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice.

Authors:  E Kedar; O Palgi; G Golod; I Babai; Y Barenholz
Journal:  J Immunother       Date:  1997-05       Impact factor: 4.456

4.  Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots.

Authors:  G Rouser; S Fkeischer; A Yamamoto
Journal:  Lipids       Date:  1970-05       Impact factor: 1.880

5.  Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo.

Authors:  S Hockertz; G Franke; E Kniep; M L Lohmann-Matthes
Journal:  J Interferon Res       Date:  1989-10

6.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.

Authors:  S A Rosenberg; D E White
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-01

7.  Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.

Authors:  R Kurzrock; M G Rosenblum; S A Sherwin; A Rios; M Talpaz; J R Quesada; J U Gutterman
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

Review 8.  Clinical toxicity of interferons in cancer patients: a review.

Authors:  J R Quesada; M Talpaz; A Rios; R Kurzrock; J U Gutterman
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

9.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors.

Authors:  H Karasuyama; F Melchers
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

10.  Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells.

Authors:  A Porgador; B Gansbacher; R Bannerji; E Tzehoval; E Gilboa; M Feldman; L Eisenbach
Journal:  Int J Cancer       Date:  1993-02-01       Impact factor: 7.396

View more
  12 in total

1.  Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.

Authors:  Jin-Kun Zhang; Jun Li; Juan Zhang; Hai-Bin Chen; Su-Biao Chen
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus.

Authors:  S Segura; C Gamazo; J M Irache; S Espuelas
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A.

Authors:  Karen White; Thomas Rades; Philip Kearns; Istvan Toth; Sarah Hook
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 4.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

5.  Chitosan solution enhances the immunoadjuvant properties of GM-CSF.

Authors:  David A Zaharoff; Connie J Rogers; Kenneth W Hance; Jeffrey Schlom; John W Greiner
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

6.  Lysine: Is it worth more?

Authors:  D Datta; A Bhinge; V Chandran
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

7.  Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.

Authors:  Lakshmi Krishnan; Lise Deschatelets; Felicity C Stark; Komal Gurnani; G Dennis Sprott
Journal:  Clin Dev Immunol       Date:  2011-01-18

8.  Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch.

Authors:  Chia-Hung Chen; Yu-Ling Lin; Yen-Ku Liu; Pei-Juin He; Ching-Min Lin; Yi-Han Chiu; Chang-Jer Wu; Tian-Lu Cheng; Shih-Jen Liu; Kuang-Wen Liao
Journal:  Int J Nanomedicine       Date:  2012-02-03

Review 9.  Stimulating antitumor immunity with nanoparticles.

Authors:  Mee Rie Sheen; Patrick H Lizotte; Seiko Toraya-Brown; Steven Fiering
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-05-21

Review 10.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.

Authors:  Flávia Castro; Ana Patrícia Cardoso; Raquel Madeira Gonçalves; Karine Serre; Maria José Oliveira
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.